Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Head & Neck 1

Conditions

Stomatitis 2Neoplasms 2Mucositis 2Colorectal Neoplasms 2Vulvodynia 1Pain 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Mobility Limitation 1Lymphoma 1Lung Neoplasms 1Leukemia 1Hematologic Diseases 1Head and Neck Neoplasms 1Dyspareunia 1Disease 1Carcinoma, Non-Small-Cell Lung 1Cancer Pain 1Breast Neoplasms 1

Interventions

Cisplatin 75Cetuximab 63Radiotherapy 38pembrolizumab 29Radiotherapy, Intensity-Modulated 28Carboplatin 25Fluorouracil 24Docetaxel 24Paclitaxel 19Erlotinib Hydrochloride 13Nivolumab 12Radiation 10Pemetrexed 10durvalumab 8Gemcitabine 8Drug Therapy 8Bevacizumab 7zalutumumab 6Surgical Procedures, Operative 6Panitumumab 6Lapatinib 6Everolimus 6Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6epacadostat 5Standard of Care 5Oxaliplatin 5Gefitinib 5Afatinib 5Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Head and Neck Neoplasms × Water × Clear all
NCT02324335 2019-01-16

Brilacidin

Innovation Pharmaceuticals, Inc.

Phase 2 Completed
61 enrolled 12 charts
Head & NeckOther

Head and Neck Neoplasms, Stomatitis, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡